SNYR
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/B of -0.26 indicates the company owes more than it owns.
- Negative P/B ratio
- No Graham Number available due to negative earnings/equity
Growth metrics are trending sharply downward across all timeframes.
- Revenue growth -41% YoY
- EPS growth -391.7% YoY
- Consistent earnings misses
Long-term historical trend is a near-total loss of shareholder value.
- Brief period of EPS beats in early 2025
- 5Y Change of -94.2%
- 1M Change of -60.5%
F-Score of 1/9 is a deterministic signal of extreme financial weakness.
- Current Ratio > 1
- Piotroski F-Score 1/9
- Negative ROA (-39.89%)
- Quick Ratio below 1.0 (0.71)
Company is not in a position to return capital.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SNYR and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SNYR
Synergy CHC Corp.
Primary
|
-94.2% | -94.2% | -78.9% | -80.5% | -60.5% | -8.7% |
|
BIAF
bioAffinity Technologies, Inc.
Peer
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
|
QUCY
Mainz Biomed N.V.
Peer
|
-98.2% | -91.0% | -84.9% | -67.3% | -19.4% | +9.9% |
|
BRTX
BioRestorative Therapies, Inc.
Peer
|
-99.5% | -93.0% | -85.2% | -84.5% | +8.1% | -7.9% |
|
MLEC
Moolec Science SA
Peer
|
-99.5% | -98.7% | -93.0% | -33.2% | -26.5% | -34.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SNYR
Synergy CHC Corp.
|
BEARISH | $5.93M | - | -% | -40.6% | $0.52 | |
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 | Compare |
|
QUCY
Mainz Biomed N.V.
|
BEARISH | $6.09M | - | -488.3% | -% | $0.49 | Compare |
|
BRTX
BioRestorative Therapies, Inc.
|
BEARISH | $6.39M | - | -320.5% | -% | $0.25 | Compare |
|
MLEC
Moolec Science SA
|
BEARISH | $5.46M | - | -% | -% | $7.52 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning SNYR from our newsroom.